Literature DB >> 31932427

TrkB hyperactivity contributes to brain dysconnectivity, epileptogenesis, and anxiety in zebrafish model of Tuberous Sclerosis Complex.

Magdalena Kedra1, Katarzyna Banasiak1, Katarzyna Kisielewska1, Lidia Wolinska-Niziol1, Jacek Jaworski2, Justyna Zmorzynska2.   

Abstract

Tuberous Sclerosis Complex (TSC) is a rare genetic disease that manifests with early symptoms, including cortical malformations, childhood epilepsy, and TSC-associated neuropsychiatric disorders (TANDs). Cortical malformations arise during embryonic development and have been linked to childhood epilepsy before, but the underlying mechanisms of this relationship remain insufficiently understood. Zebrafish have emerged as a convenient model to study elementary neurodevelopment; however, without in-depth functional analysis, the Tsc2-deficient zebrafish line cannot be used for studies of TANDs or new drug screening. In this study, we found that the lack of Tsc2 in zebrafish resulted in heterotopias and hyperactivation of the mTorC1 pathway in pallial regions, which are homologous to the mammalian cortex. We observed commissural thinning that was responsible for brain dysconnectivity, recapitulating TSC pathology in human patients. The lack of Tsc2 also delayed axonal development and caused aberrant tract fasciculation, corresponding to the abnormal expression of genes involved in axon navigation. The mutants underwent epileptogenesis that resulted in nonmotor seizures and exhibited increased anxiety-like behavior. We further mapped discrete parameters of locomotor activity to epilepsy-like and anxiety-like behaviors, which were rescued by reducing tyrosine receptor kinase B (TrkB) signaling. Moreover, in contrast to treatment with vigabatrin and rapamycin, TrkB inhibition rescued brain dysconnectivity and anxiety-like behavior. These data reveal that commissural thinning results in the aberrant regulation of anxiety, providing a mechanistic link between brain anatomy and human TANDs. Our findings also implicate TrkB signaling in the complex pathology of TSC and reveal a therapeutic target.
Copyright © 2020 the Author(s). Published by PNAS.

Entities:  

Keywords:  TANDs; TrkB; Tuberous Sclerosis Complex; anxiety; brain dysconnectivity

Mesh:

Substances:

Year:  2020        PMID: 31932427      PMCID: PMC6995026          DOI: 10.1073/pnas.1910834117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder that is caused by loss-of-function mutations in the TSC1 or TSC2 genes (1), the products of which form a complex that negatively regulates mechanistic/mammalian target of rapamycin (mTOR) complex 1 (mTORC1), a complex necessary for proper neuronal development (2). In TSC, epilepsy is the most prominent neurological symptom, which begins in the first year of life and often evolves into an intractable form (3). Epilepsy is accompanied by TSC-associated neuropsychiatric disorders (TANDs), including intellectual disability (ID) and anxiety (4). Epilepsy is thought to be caused by cortical malformations (5) that consist of heterotopias, tubers, and white matter (WM) dysconnectivity in TSC (4). Tubers are often diagnosed in utero, suggesting that the pathology of TSC is acquired during embryonic development (6). Cortical malformations result in childhood epilepsy and intractable or treatment-refractory seizures in various other diseases, underscoring the importance of proper cortex development (5). The existing mammalian models of TSC mimic human disease in many aspects, including cortical malformations and seizures (7–13). However, these models present difficulties in studying TSC pathology during embryonic development in utero when cortical malformations that lead to epileptogenesis arise (14). Thus, the present study comprehensively examined brain development and behavior in zebrafish, which provide an opportunity to study early neuronal development in vivo due to external development and body transparency. Although zebrafish do not contain a cortex per se, the homologous structures are present, the majority of which are localized to the pallium (15–17). Previous studies investigated the utility of tsc2 mutant zebrafish as a model of TSC and reported abnormalities in pallial WM organization (including the disruption of WM with ectopic cell bodies), a decrease in locomotion, and abnormal brain activity in the optic tectum (18, 19). However, these studies did not elaborate potential disease mechanisms. Moreover, neurobehavioral changes that mimic symptoms of human TANDs were not investigated in tsc2 mutants. Therefore, in this study, we performed an in-depth analysis of changes in brain connectivity during development. We evaluated tsc2 fish behavior and mapped seizure activity and anxiety-like behavior to discrete parameters of locomotion. Finally, we tested the ability of drugs to rescue TSC-associated phenotypes and found that reducing tyrosine receptor kinase B (TrkB) signaling reversed brain dysconnectivity, epileptogenesis, and anxiety-like behavior. The latter phenotype was also reversed by inhibition of Rac1, which is potentially one of the downstream targets of TrkB.

Results

Lack of Tsc2 Leads to White Matter Disruption and Brain Dysconnectivity in Zebrafish.

A disruption of WM organization is a common feature of TSC and was previously found in the telencephalon in tsc2 mutants (19). Indeed, when we examined the telencephalon in tsc2 fish, we confirmed the presence of ectopic cell bodies in tsc2 by two-dimensional (2D) brain section imaging (Fig. 1) and three-dimensional (3D) whole-brain imaging (). These cells presented higher levels of phosphorylated ribosomal protein s6 at serines 235 and 236 (P-Rps6; Fig. 1 and ), representing the hyperactivation of mTorC1. The P-Rps6–positive cells in the pallium of tsc2 mutants had higher intensity signals and larger cell bodies compared with pallial cells of tsc2 fish (Fig. 1 and ). We also measured the thickness of the main brain commissures because human TSC patients exhibit WM dysconnectivity that is associated with epileptic seizures and worse cognitive outcomes (12, 20–22). The tsc2 anterior commissure (AC) that connects the brain hemispheres in the telencephalon was thinner than in tsc2 fish (Fig. 2 and ). The postoptic commissure was also thinner in tsc2 mutants, whereas the size of the lateral tracts was similar to tsc2 fish (). The higher number of P-Rps6–positive cells negatively correlated with AC thickness, revealed by double immunostaining (Fig. 2 ).
Fig. 1.

tsc2 exhibit WM disruption and mTorC1 activation in the pallium. (A) Organization of gray matter and WM in coronal section through the AC. Circles represent cell bodies. Sample photographs of tsc2 brain sections that were stained with DAPI are shown, together with the relative number of cell bodies in WM compartments in tsc2 brains [H = 24.443, P = 4.92 × 10−6; P = 3.1 × 10−6 for tsc2 vs. tsc2, P = 0.017 for tsc2 vs. tsc (Dunn’s test)]. (Scale bar, 40 μm.) (B) Representative images of coronal tsc2 sections through the pallium that were immunostained with anti–P-Rps6 antibody (green). S, subpallium. [Scale bars, 40 and 20 μm (magnification).] (C) The number of P-Rps6–positive neurons in the telencephalon in tsc2 [H = 18.88, P = 7.95 × 10−5; P = 0.00071 for tsc2 vs. tsc2, P = 0.00117 for tsc2 vs. tsc2 (Dunn’s test)]. (D) Mean phosphorylation levels of P-Rps6 per cell per fish in the telencephalon in tsc2 [F = 6.772, P = 0.00335; P = 0.0019 for tsc2 vs. tsc2, P = 0.0696 for tsc2 vs. tsc2 (Dunnett’s test)]. (E) Mean soma size of P-Rps6–positive neurons per fish in the telencephalon in tsc2 [F = 21.48, P = 9.3 × 10−7; P = 4.1 × 10−7 for tsc2 vs. tsc2, P = 0.133 for tsc2 vs. tsc2 (Dunnett’s test)]. *P < 0.05, ***P < 0.005.

Fig. 2.

tsc2 exhibit WM dysconnectivity resulting from aberrant axon elongation. (A) Representative horizontal optical sections through tsc2 brains that were double-immunostained with anti–acetylated-Tubulin (ac-Tubulin; red) and anti–P-Rps6 (green) antibodies that show the AC (dashed lines) at 7.5 days post fertilization, together with the quantification of the width of the AC [F = 4.053, P = 0.0202; P = 0.011 for tsc2 vs. tsc2 (Dunnett’s test)]. (Scale bars, 30 μm.) (B) Correlation analysis of the number of P-Rps6–positive cells in the brain and the width of the AC, showing negative Spearman correlation and genotype clustering. (C) Schematic diagram of the localization of ptf1a:GFP-positive neurons in the posterior tuberculum that extend their axons dorsally and cross the brain midline through the posterior commissure. (D) Representative confocal images of a dorsal view of ptf1a:GFP-positive axons that show axonal tract fasciculation at the midline. The frequency of various ptf1a:GFP axonal phenotypes with various severity was quantified. (Scale bar, 25 μm.) (E) Sholl analysis of ptf1a:GFP-positive axon bundles at the midline of the tsc2 brains, including the number of intersections over the 3D distance from the soma [regression curves with confidence intervals; F = 23.84, P = 7.4 × 10−11; P = 2.3 × 10−6, tsc2 vs. tsc2 (Dunnett’s test); n = 16 tsc2, n = 13 tsc2, n = 15 tsc2] and the mean number of intersections with the data distribution. For tsc2, the Sholl function converged on the value of 2 at a distance of 80 to 90 μm, representing two tracts that crossed the midline, one for each hemisphere. tsc2 fish did not present this tendency, and the average number of axons at the midline was higher than in tsc2. (F) Frequency of parallelization of ptf1a:GFP tracts from each hemisphere in the posterior commissure in the brain in tsc2 fish (n = 27 tsc2, n = 31 tsc2, n = 18 tsc2). (G) Schematic diagram of the localization of ath5:gap-RFP-positive commissures in the brain in tsc2 fish at 24 hpf. op, olfactory placodes; v, brain ventricle. (H) Representative confocal images of a frontal view of ath5:gap-RFP–positive neurons that show axon elongation (white arrows indicate axons) and the occurrence of various axonal phenotypes during olfactory medial tract development [genotype × phenotype: F = 8.677, P = 8.5 × 10−4; P = 0.077, tsc2 vs. tsc2 (Dunnett’s test); n = 18 tsc2, n = 60 tsc2, n = 25 tsc2]. (Scale bars, 100 μm.) *P < 0.05, ***P < 0.005.

tsc2 exhibit WM disruption and mTorC1 activation in the pallium. (A) Organization of gray matter and WM in coronal section through the AC. Circles represent cell bodies. Sample photographs of tsc2 brain sections that were stained with DAPI are shown, together with the relative number of cell bodies in WM compartments in tsc2 brains [H = 24.443, P = 4.92 × 10−6; P = 3.1 × 10−6 for tsc2 vs. tsc2, P = 0.017 for tsc2 vs. tsc (Dunn’s test)]. (Scale bar, 40 μm.) (B) Representative images of coronal tsc2 sections through the pallium that were immunostained with anti–P-Rps6 antibody (green). S, subpallium. [Scale bars, 40 and 20 μm (magnification).] (C) The number of P-Rps6–positive neurons in the telencephalon in tsc2 [H = 18.88, P = 7.95 × 10−5; P = 0.00071 for tsc2 vs. tsc2, P = 0.00117 for tsc2 vs. tsc2 (Dunn’s test)]. (D) Mean phosphorylation levels of P-Rps6 per cell per fish in the telencephalon in tsc2 [F = 6.772, P = 0.00335; P = 0.0019 for tsc2 vs. tsc2, P = 0.0696 for tsc2 vs. tsc2 (Dunnett’s test)]. (E) Mean soma size of P-Rps6–positive neurons per fish in the telencephalon in tsc2 [F = 21.48, P = 9.3 × 10−7; P = 4.1 × 10−7 for tsc2 vs. tsc2, P = 0.133 for tsc2 vs. tsc2 (Dunnett’s test)]. *P < 0.05, ***P < 0.005. tsc2 exhibit WM dysconnectivity resulting from aberrant axon elongation. (A) Representative horizontal optical sections through tsc2 brains that were double-immunostained with anti–acetylated-Tubulin (ac-Tubulin; red) and anti–P-Rps6 (green) antibodies that show the AC (dashed lines) at 7.5 days post fertilization, together with the quantification of the width of the AC [F = 4.053, P = 0.0202; P = 0.011 for tsc2 vs. tsc2 (Dunnett’s test)]. (Scale bars, 30 μm.) (B) Correlation analysis of the number of P-Rps6–positive cells in the brain and the width of the AC, showing negative Spearman correlation and genotype clustering. (C) Schematic diagram of the localization of ptf1a:GFP-positive neurons in the posterior tuberculum that extend their axons dorsally and cross the brain midline through the posterior commissure. (D) Representative confocal images of a dorsal view of ptf1a:GFP-positive axons that show axonal tract fasciculation at the midline. The frequency of various ptf1a:GFP axonal phenotypes with various severity was quantified. (Scale bar, 25 μm.) (E) Sholl analysis of ptf1a:GFP-positive axon bundles at the midline of the tsc2 brains, including the number of intersections over the 3D distance from the soma [regression curves with confidence intervals; F = 23.84, P = 7.4 × 10−11; P = 2.3 × 10−6, tsc2 vs. tsc2 (Dunnett’s test); n = 16 tsc2, n = 13 tsc2, n = 15 tsc2] and the mean number of intersections with the data distribution. For tsc2, the Sholl function converged on the value of 2 at a distance of 80 to 90 μm, representing two tracts that crossed the midline, one for each hemisphere. tsc2 fish did not present this tendency, and the average number of axons at the midline was higher than in tsc2. (F) Frequency of parallelization of ptf1a:GFP tracts from each hemisphere in the posterior commissure in the brain in tsc2 fish (n = 27 tsc2, n = 31 tsc2, n = 18 tsc2). (G) Schematic diagram of the localization of ath5:gap-RFP-positive commissures in the brain in tsc2 fish at 24 hpf. op, olfactory placodes; v, brain ventricle. (H) Representative confocal images of a frontal view of ath5:gap-RFP–positive neurons that show axon elongation (white arrows indicate axons) and the occurrence of various axonal phenotypes during olfactory medial tract development [genotype × phenotype: F = 8.677, P = 8.5 × 10−4; P = 0.077, tsc2 vs. tsc2 (Dunnett’s test); n = 18 tsc2, n = 60 tsc2, n = 25 tsc2]. (Scale bars, 100 μm.) *P < 0.05, ***P < 0.005. To evaluate axon development that may underlie WM thinning, we crossed the tsc2 line into transgenic Tg(ptf1a:GFP) background and examined them by live light-sheet imaging. ptf1a:GFP-positive neurons in the posterior tuberculum extend their axons toward the posterior commissure, where they cross the brain midline and innervate the other hemisphere (Fig. 2). In tsc2, ptf1a:GFP-positive axons from one hemisphere crossed the brain boundary in one bundle. The same axons in tsc2 presented disturbances in tract fasciculation (Fig. 2). We were able to distinguish mild axonal phenotypes (e.g., one axon did not cross the midline in the bundle) and severe disturbances in axon bundling (e.g., axons crossed the midline stochastically; ). Quantitative morphological analysis of ptf1a:GFP-positive axons of tsc2 confirmed the impaired tract fasciculation in tsc2 fish, reflected by a higher number of intersections at the midline compared with tsc2 (Fig. 2). Moreover, ptf1a:GFP-positive bundles in tsc2 did not form parallel tracts, in contrast to tsc2, which presented two parallel tracts (Fig. 2). To determine whether impairments in axonal development are a general phenotype of the mutants, we explored the axonal development of ath5:gap-RFP–positive olfactory neurons in Tg(ath5:gap-RFP);tsc2 zebrafish starting from 24 h post fertilization (hpf) when these neurons extended their axons to contact each other and crossed the hemisphere boundary through the AC, pioneering medial olfactory tracts (Fig. 2). In living tsc2 mutants, ath5:gap-RFP–positive neurons more often extended their axons improperly in various directions or did not extend them at all compared with tsc2 (Fig. 2 and ). This phenomenon persisted at 27 hpf, when ath5:gap-RFP–positive axons contacted each other at the midline, forming one tract in tsc2 fish but not in tsc2 or tsc2, in which they were disturbed and exhibited deficient crossing of the midline (). The impairments in tract fasciculation were unrelated to disturbances in glial bridges, which were properly formed at the brain midline allowing axons to cross it (). These findings suggest deficiencies in sensing or responding to axon guidance cues. Higher messenger RNA (mRNA) levels of the dock3, dock4, and elmo2 genes, which are implicated in the Rac1-associated response to guidance cues, further support this hypothesis (). The increased expression of Dock4 and Elmo2 proteins was confirmed in the telencephalon of tsc2 compared to controls (). In tsc2, Elmo2-positive foci were found in the AC, while they were absent there in the tsc2. Altogether, our results suggest that the lack of Tsc2 leads to commissural thinning and brain dysconnectivity, likely caused by disturbances in axon guidance signaling.

Increase in Epileptogenesis in tsc2 Zebrafish Leads to Absence Seizures.

Alterations of brain connectivity may result in epileptogenesis. Thus, we examined the basal activity in tsc2 fish and confirmed decreased locomotion in tsc2 (Fig. 3), which was independent of motor and vision defects (). We also examined fish velocity within various ranges to describe the behavior in more detail (23). The average velocity of hyperactive movements (>2 cm/s) in tsc2 was higher than the average velocities of tsc2 or tsc2 fish (Fig. 3), although the duration of tsc2 activity decreased within this velocity range as well (). These data suggest that tsc2 move in a burst-like manner, which may represent seizure-like or anxiety-like behavior.
Fig. 3.

tsc2 exhibit decrease in activity, increase in epileptogenesis, and increase in response to ethosuximide treatment. (A) Activity analysis of tsc2 fish that shows activity vs. time [F = 2.601, P = 0.0067; P = 2.38 × 10−9 for tsc2 vs. tsc2, P = 7.42 × 10−6 for tsc2 vs. tsc2 (Dunnett’s test)] and cumulative activity [F = 18.61, P = 4.76 × 10−8; P = 4.16 × 10−8 for tsc2 vs. tsc2, P = 1.22 × 10−6 for tsc2 vs. tsc2+/+ (Dunnett’s test)] in tsc2 fish (n = 32) compared with tsc2 fish (n = 85) and tsc2+/+ control siblings (n = 50) during 1 h of tracking. (B) Average velocity of high-velocity movements (>2 cm/s) of tsc2 fish compared with tsc2 and tsc2 controls [H = 31.73, P = 1.29 × 10−7; P = 4.8 × 10−6 for tsc2 vs. tsc2, P = 2.1 × 10−7 for tsc2 vs. tsc2 (Dunn’s test)]. (C) Representative images that show neuronal activity (without any stimulation) in the pallium in tsc2 fish and the mean number of active cells, which increases in tsc2 [F = 9.638, P = 0.0074; P = 0.009 for tsc2 vs. tsc2, P = 0.012 for tsc2 vs. tsc2 (Dunnett’s test)]. (Scale bar, 30 µm.) (D) Exemplary time-lapse photographs of STFBC of tsc2 fish and quantification at 24 hpf [F = 8.59, P = 5 × 10−4; P ≤ 0.001 for tsc2 vs. other genotypes (Dunnett’s test)] and 32 hpf [F = 7.535, P = 0.001; P = 0.012 for tsc2 vs. tsc2, P = 4 × 10−4 for tsc2 vs. tsc2 (Dunnett’s test)]. (Scale bar, 100 μm.) (E) Representative tracks for each tsc2 genotype after treatment with PTZ representing the entire 20 min and the first 5 s of tracking, showing the number of PTZ-induced seizure-like outbursts in the first 10 min of tracking for tsc2 fish compared with tsc2 and tsc2 fish [H = 34.667, P = 3 × 10−8; P = 6.8 × 10−6 for tsc2 vs. tsc2, P = 9.1 × 10−8 for tsc2 vs. tsc2 (Dunn’s test)]. Red tracks represent high-velocity movements (>2 cm/s). Green tracks indicate free swimming (movement within a range of 0.5 to 2 cm/s). Black tracks indicate free floating (<0.5 cm/s). (F) Time to first PTZ-induced outburst for tsc2 compared with control siblings [H = 26.838, P = 1.49 × 10−6; P = 3 × 10−4 for tsc2 vs. tsc2, P = 2.1 × 10−6 for tsc2 vs. tsc2 (Dunn’s test)]. (G) Activity analysis of tsc2 fish that were treated with ethosuximide, showing activity vs. time and cumulative activity of tsc2 (n = 32) compared with tsc2 (n = 56) and tsc2 (n = 25) over 1 h of tracking. An increase in activity after acute ethosuximide treatment is considered to represent anxiety-like behavior, reflected by hyperactivity regardless of genotype (H = 40.312, P = 9.15 × 10−9; P = 3.9 × 10−9 for tsc2 untreated vs. treated with ethosuximide acutely, P > 0.05 for tsc2 untreated vs. treated with ethosuximide for 24 h [Dunn’s test]). (H) Average velocity of high-velocity movements (>2 cm/s) of tsc2 compared with tsc2 and tsc2 fish after ethosuximide treatment [H = 9.5556, P = 0.02275; P = 0.08 for tsc2 untreated vs. treated with ethosuximide acutely, P > 0.05 for tsc2 untreated vs. treated with ethosuximide for 24 h (Dunn’s test)]. (I) Survival probability of tsc2 fish after ethosuximide treatment vs. vehicle treatment. *P < 0.05, **P < 0.01, ***P < 0.005.

tsc2 exhibit decrease in activity, increase in epileptogenesis, and increase in response to ethosuximide treatment. (A) Activity analysis of tsc2 fish that shows activity vs. time [F = 2.601, P = 0.0067; P = 2.38 × 10−9 for tsc2 vs. tsc2, P = 7.42 × 10−6 for tsc2 vs. tsc2 (Dunnett’s test)] and cumulative activity [F = 18.61, P = 4.76 × 10−8; P = 4.16 × 10−8 for tsc2 vs. tsc2, P = 1.22 × 10−6 for tsc2 vs. tsc2+/+ (Dunnett’s test)] in tsc2 fish (n = 32) compared with tsc2 fish (n = 85) and tsc2+/+ control siblings (n = 50) during 1 h of tracking. (B) Average velocity of high-velocity movements (>2 cm/s) of tsc2 fish compared with tsc2 and tsc2 controls [H = 31.73, P = 1.29 × 10−7; P = 4.8 × 10−6 for tsc2 vs. tsc2, P = 2.1 × 10−7 for tsc2 vs. tsc2 (Dunn’s test)]. (C) Representative images that show neuronal activity (without any stimulation) in the pallium in tsc2 fish and the mean number of active cells, which increases in tsc2 [F = 9.638, P = 0.0074; P = 0.009 for tsc2 vs. tsc2, P = 0.012 for tsc2 vs. tsc2 (Dunnett’s test)]. (Scale bar, 30 µm.) (D) Exemplary time-lapse photographs of STFBC of tsc2 fish and quantification at 24 hpf [F = 8.59, P = 5 × 10−4; P ≤ 0.001 for tsc2 vs. other genotypes (Dunnett’s test)] and 32 hpf [F = 7.535, P = 0.001; P = 0.012 for tsc2 vs. tsc2, P = 4 × 10−4 for tsc2 vs. tsc2 (Dunnett’s test)]. (Scale bar, 100 μm.) (E) Representative tracks for each tsc2 genotype after treatment with PTZ representing the entire 20 min and the first 5 s of tracking, showing the number of PTZ-induced seizure-like outbursts in the first 10 min of tracking for tsc2 fish compared with tsc2 and tsc2 fish [H = 34.667, P = 3 × 10−8; P = 6.8 × 10−6 for tsc2 vs. tsc2, P = 9.1 × 10−8 for tsc2 vs. tsc2 (Dunn’s test)]. Red tracks represent high-velocity movements (>2 cm/s). Green tracks indicate free swimming (movement within a range of 0.5 to 2 cm/s). Black tracks indicate free floating (<0.5 cm/s). (F) Time to first PTZ-induced outburst for tsc2 compared with control siblings [H = 26.838, P = 1.49 × 10−6; P = 3 × 10−4 for tsc2 vs. tsc2, P = 2.1 × 10−6 for tsc2 vs. tsc2 (Dunn’s test)]. (G) Activity analysis of tsc2 fish that were treated with ethosuximide, showing activity vs. time and cumulative activity of tsc2 (n = 32) compared with tsc2 (n = 56) and tsc2 (n = 25) over 1 h of tracking. An increase in activity after acute ethosuximide treatment is considered to represent anxiety-like behavior, reflected by hyperactivity regardless of genotype (H = 40.312, P = 9.15 × 10−9; P = 3.9 × 10−9 for tsc2 untreated vs. treated with ethosuximide acutely, P > 0.05 for tsc2 untreated vs. treated with ethosuximide for 24 h [Dunn’s test]). (H) Average velocity of high-velocity movements (>2 cm/s) of tsc2 compared with tsc2 and tsc2 fish after ethosuximide treatment [H = 9.5556, P = 0.02275; P = 0.08 for tsc2 untreated vs. treated with ethosuximide acutely, P > 0.05 for tsc2 untreated vs. treated with ethosuximide for 24 h (Dunn’s test)]. (I) Survival probability of tsc2 fish after ethosuximide treatment vs. vehicle treatment. *P < 0.05, **P < 0.01, ***P < 0.005. Neuronal hyperexcitability was previously reported in the optic tectum in tsc2 fish (18). We instead examined pallium activity because the cortex in human TSC patients is thought to be the prime pathology region. We performed 3D time-lapse imaging of neuronal activity, using tsc2;Tg(GCaMP5G) fish. Pallial neurons in tsc2 exhibited hyperexcitability compared with controls (Fig. 3 and ). We also examined fish for signs of epileptogenesis at early development as cortical malformations in TSC that lead to epileptogenesis are thought to start early. We quantified spontaneous tail flicks and body coils (STFBC) because they were previously shown to correlate with epilepsy (24). The tsc2 exhibited an increase in STFBC number (Fig. 3). To further test whether tsc2 are more susceptible to seizures, we exposed tsc2 fish to γ-aminobutyric-acid receptor antagonist pentylenetetrazole (PTZ), which evokes clonic-like seizures in fish (25). tsc2 exhibited more PTZ-induced high-velocity outbursts that began much earlier than in the controls (Fig. 3 ). tsc2 exhibited epileptogenesis and decreased activity, suggesting that nonmotor seizures may produce this phenotype. To test this possibility, we treated the fish with ethosuximide, a highly selective drug that is used to treat absence seizures in humans (26). Acute treatment with ethosuximide caused hyperactivity, whereas longer treatment rescued tsc2 activity to levels that were similar to controls (Fig. 3). Ethosuximide also rescued early mortality of tsc2 (Fig. 3 and ). However, the increase in high-speed velocity of tsc2 fish did not recover after ethosuximide (Fig. 3), suggesting that complex partial seizures or anxiety are responsible for this phenotype.

tsc2 Fish Exhibit an Increase in Anxiety-Like Behavior.

The increase in velocity of tsc2 may represent anxiety-like behavior, which has not been previously reported in Tsc2-deficient zebrafish. We observed disturbances in the axonal development of ptf1a:GFP-positive neurons in the posterior tuberculum in tsc2 (Fig. 2 ), which may result in alterations of connectivity of the fear/anxiety response axis (27). We evaluated whether tsc2 exhibit anxiety-like behavior by subjecting tsc2 fish to a light-preference test. tsc2+/+ fish spent more time in the light compartment, reflecting phototaxia. tsc2v spent more time in the dark compartment compared with tsc2 (Fig. 4), indicating that they were indifferent to light and implying decreased anxiety-like behavior. We also found that tsc2 movements were more confined to the peripheral areas of the well compared with tsc2+/+, suggesting increased anxiety-like behavior. We then analyzed the activity of tsc2 fish in an open field to test anxiety-like behavior that is related to a novel environment and open areas. tsc2 spent less time exploring and spent more time near the edges compared with tsc2 (Fig. 4), suggesting increased anxiety-like behavior.
Fig. 4.

Mutant tsc2 exhibit an increase in anxiety-like behavior in the open field and in response to sudden changes in light conditions and an increase in cortisol levels. (A) Light-preference analysis of tsc2 fish, including representative tracks and time spent in the light and dark compartments (relative to total activity) for each tsc2 genotype [genotype × treatment: F = 8.181, P = 5 × 10−4; P = 1 × 10−4 for tsc2 light vs. dark, P = 3 × 10−4 for tsc2 light vs. dark, P = 0.999 for tsc2 light vs. dark (Tukey HSD test); n = 15/genotype]. The data are expressed as mean ± SEM. (B) Schematic diagram of the open field analysis of tsc2 fish that shows selections of the peripheral (surround) and central (center) areas of the experimental well, time spent in the peripheral and central areas of the well (relative to total activity) for each tsc2 genotype (mean ± SEM), and data distribution of the time spent in the peripheral area relative to total activity of tsc2 fish [F = 3.721, P = 0.0321; P = 0.043 for tsc2 vs. tsc2, P = 0.11 for tsc2 vs. tsc2 (Tukey HSD test); n = 15/genotype]. (C) Mean activity over time for each tsc2 genotype after sudden changes in light conditions [H = 636.14, P < 2.2 × 10−16; P < 7.4 × 10−8 for tsc2 vs. tsc2 or tsc2 (Dunn’s test); n = 23 tsc2, n = 69 tsc2, n = 45 tsc2]. (D) Mean activity over time for tsc2 that were subjected to sudden changes in light conditions after treatment with anxiety-modulating drugs compared with untreated fish [H = 492.92, P < 2.2 × 10−16; P < 2 × 10−16, untreated vs. treated (Dunn’s test)]. (E) Amplitudes of activity in the dark and light phases in tsc2 fish after treatment with various anxiety-modulating drugs compared with untreated fish [genotype × treatment: F = 1.806, P = 0.128; treatment: F = 43.643, P < 2 × 10−16; P = 0.0067 for untreated tsc2 vs. tsc2; P = 1.3 × 10−5 for untreated tsc2 vs. treated with diazepam; P = 0.999, untreated tsc2 vs. treated with RA (Tukey HSD test)]. (F) Quantification of cortisol levels in tsc2 fish [F = 3.395, P = 0.103; P = 0.081, tsc2 vs. tsc2 (Dunnett’s test); n = 120/genotype]. *P < 0.05, **P < 0.01, ***P < 0.005, ns: not significant.

Mutant tsc2 exhibit an increase in anxiety-like behavior in the open field and in response to sudden changes in light conditions and an increase in cortisol levels. (A) Light-preference analysis of tsc2 fish, including representative tracks and time spent in the light and dark compartments (relative to total activity) for each tsc2 genotype [genotype × treatment: F = 8.181, P = 5 × 10−4; P = 1 × 10−4 for tsc2 light vs. dark, P = 3 × 10−4 for tsc2 light vs. dark, P = 0.999 for tsc2 light vs. dark (Tukey HSD test); n = 15/genotype]. The data are expressed as mean ± SEM. (B) Schematic diagram of the open field analysis of tsc2 fish that shows selections of the peripheral (surround) and central (center) areas of the experimental well, time spent in the peripheral and central areas of the well (relative to total activity) for each tsc2 genotype (mean ± SEM), and data distribution of the time spent in the peripheral area relative to total activity of tsc2 fish [F = 3.721, P = 0.0321; P = 0.043 for tsc2 vs. tsc2, P = 0.11 for tsc2 vs. tsc2 (Tukey HSD test); n = 15/genotype]. (C) Mean activity over time for each tsc2 genotype after sudden changes in light conditions [H = 636.14, P < 2.2 × 10−16; P < 7.4 × 10−8 for tsc2 vs. tsc2 or tsc2 (Dunn’s test); n = 23 tsc2, n = 69 tsc2, n = 45 tsc2]. (D) Mean activity over time for tsc2 that were subjected to sudden changes in light conditions after treatment with anxiety-modulating drugs compared with untreated fish [H = 492.92, P < 2.2 × 10−16; P < 2 × 10−16, untreated vs. treated (Dunn’s test)]. (E) Amplitudes of activity in the dark and light phases in tsc2 fish after treatment with various anxiety-modulating drugs compared with untreated fish [genotype × treatment: F = 1.806, P = 0.128; treatment: F = 43.643, P < 2 × 10−16; P = 0.0067 for untreated tsc2 vs. tsc2; P = 1.3 × 10−5 for untreated tsc2 vs. treated with diazepam; P = 0.999, untreated tsc2 vs. treated with RA (Tukey HSD test)]. (F) Quantification of cortisol levels in tsc2 fish [F = 3.395, P = 0.103; P = 0.081, tsc2 vs. tsc2 (Dunnett’s test); n = 120/genotype]. *P < 0.05, **P < 0.01, ***P < 0.005, ns: not significant. Phototaxic zebrafish larvae exhibit anxiety-like behavior when subjected to a dark environment, resulting in hyperactivity. Switching the light on causes freezing because the sudden change in lighting conditions augments anxiety-like behavior even further, which is innately perceived by the fish as dangerous (27). tsc2 mutants exhibited increased activity in the dark environment compared with tsc2. These mutants also exhibited slightly more freezing during light, but this increase was not significantly different from tsc2, which already presented very low activity (Fig. 4). To validate the experimental setup, we subjected tsc2 fish to anxiolytic diazepam or anxiogenic retinoic acid (RA). Diazepam decreased anxiety-like behavior in both the tsc2 and their control siblings, whereas RA increased anxiety-like behavior in tsc2 and tsc2. However, RA did not significantly affect tsc2, which had already exhibited increased anxiety-like behavior (Fig. 4 and ). These results were corroborated by changes in the amplitude of activity between light phases (Fig. 4). Finally, cortisol levels in tsc2 fish were elevated compared with their control siblings (Fig. 4). The results from the light-preference test (Fig. 4), sudden-light-changes test (Fig. 4), and cortisol levels (Fig. 4) suggest impairment in impulse control that contrasts with the anxiety hypothesis. To resolve this, we evaluated escape responses to repeated dark flashes and their habituation. The tsc2 exhibited lower or delayed responses to the first startle stimulus compared with tsc2, but the startle habituation was similar to that of other fish (). Although the total activity of tsc2 was lower, the fish indeed exhibited a startle response but to a lesser extent than sibling controls. These results do not confirm higher impulsivity and instead suggest that freezing behavior in response to the startle stimulus was attributable to higher preexisting levels of anxiety in tsc2. Altogether, the results confirm increased anxiety-like behavior in tsc2 compared with tsc2 and recapitulate the human phenotype of TANDs (4).

TrkB Antagonist ANA-12 Reverses TSC-Associated Phenotypes in Zebrafish.

Brain-derived neurotrophic factor (BDNF)-TrkB signaling has not been previously studied in the context of TSC, although the dysregulation of this pathway has been implicated in cell migration, axonal growth, epilepsy, and anxiety (26, 28, 29). Thus, we tested whether targeting TrkB reverses the TSC-related phenotypes that are observed in tsc2. ANA-12 is a selective antagonist of TrkB and was previously shown to exhibit anxiolytic potential in mice (29). To test the effects of ANA-12, we first examined the phosphorylation levels of TrkB by enzyme-linked immunosorbent assay (ELISA). The amino acid sequence of zebrafish TrkB shares over 60% homology with the human sequence, with highly conserved tyrosine phosphorylation motives (), which are phosphorylated upon TrkB activation. The phosphorylated TrkB (P-TrkB) levels were higher in tsc2 compared with tsc2 and lower after ANA-12 treatment (Fig. 5). To further confirm the actions of ANA-12 on the TrkB-signaling pathway, we examined the activation of cAMP-response element-binding protein (Creb), which depends on BDNF-induced TrkB activation. Creb phosphorylation at Ser111, homologous to Ser133 in mammals, was increased in tsc2 compared with controls, and ANA-12 treatment reversed this (Fig. 5 and ). These results suggest that ANA-12 produces similar effects in mammals and fish through TrkB and Creb.
Fig. 5.

ANA-12 rescues survival, brain dysconnectivity, impairment in locomotion, and anxiety-related hypervelocity in tsc2 mutants. (A) Quantification of activation of TrkB receptor judged by levels of P-TrkB and ratio of P-TrkB to TrkB by immunochemistry (ELISA) revealed higher activation levels in tsc2 fish compared with control siblings and a decrease after ANA-12 treatment [P-TrkB: H = 4.355, P = 0.049; P = 0.05, tsc2 vs. tsc2 (Dunn’s test)]; P = 0.015, tsc2 untreated vs. treated with ANA-12 (Dunn’s test); P-TrkB/TrkB: H = 5.689, P = 0.05; P = 0.05, tsc2 vs. tsc2 (Dunn’s test); P = 0.049, tsc2 untreated vs. treated with ANA-12 (Dunn’s test)]. (B) Quantification of levels of Creb phosphorylation by immunochemistry (ELISA) revealed higher levels in tsc2 compared with controls and a decrease after ANA-12 treatment [genotype: F = 3.513, P = 4.66 × 10−4; treatment: F = 14.759, P = 8.33 × 10−4; genotype × treatment: P > 0.05; P = 0.012, tsc2 after ANA-12 vs. DMSO treatment (Tukey HSD test); P = 0.033, untreated tsc2 vs. tsc2 (Tukey HSD test)]. (C) Survival probability of tsc2 after various treatments. (D) Confocal images of tsc2 brains that were immunostained with anti–P-Rps6 antibody after ANA-12 treatment. (Scale bar, 30 µm.) (E) AC width in tsc2 after various treatments, including representative confocal images and quantification [F = 5.83, P = 0.00142; P = 0.002 for DMSO vs. ANA-12, P = 0.049 for DMSO vs. Rapa pretreatment (Dunnett’s test)]. (Scale bar, 30 µm.) (F) Cumulative activity of tsc2 after treatment with ANA-12 compared with tsc2 and tsc2 fish over 1 h of tracking, showing an increase in activity of mutant fish after treatment [H = 16.652, P = 2.42 × 10−4; P = 0.0172, tsc2 untreated vs. treated with ANA-12 for 24 h (Dunn’s test)]. (G) Cumulative activity of the tsc2 after the prevention of disease development by Rapa pretreatment compared with tsc2 and tsc2 fish over 1 h of tracking, showing an increase in activity of mutant fish after treatment [H = 32.18, P = 3.9 × 10−8; P = 2.0 × 10−8 for tsc2 untreated vs. rapamycin pretreatment (Dunn’s test)]. (H) Cumulative activity of tsc2 after the treatment with VGN or VGN-P to prevent disease development, respectively, compared with tsc2 and tsc2 fish over 1 h of tracking, showing improvements in activity after short VGN treatment but toxicity after longer treatment with VGN [H = 19.262, P = 6.566 × 10−5; P = 3.4 × 10−5 for tsc2 untreated vs. treated with VGN, P > 0.05 for tsc2 untreated vs. VGN-P (Dunn’s test)]. (I) Average velocity of high-velocity movements of tsc2 compared with tsc2 and tsc2 fish after treatment with ANA-12 [H = 14.686, P = 6.47 × 10−4; P = 0.015 for tsc2 untreated vs. treated with ANA-12 for 3 h, P = 0.003 for tsc2 untreated vs. treated with ANA-12 for 24 h (Dunn’s test)]. (J) Average velocity of high-velocity movements of tsc2 fish after the prevention of disease development with Rapa pretreatment compared with tsc2 and tsc2 fish [H = 29.68, P = 4.52 × 10−5; P > 0.05 for tsc2 untreated vs. tsc2 with Rapa pretreatment (Dunn’s test)]. (K) Average velocity of high-velocity movements of tsc2 after the treatment with VGN or VGN-P to prevent disease development, respectively, compared with tsc2 and tsc2 fish (H = 3.286, P = 0.19). *P < 0.05, **P < 0.01, ***P < 0.005, ns: not significant.

ANA-12 rescues survival, brain dysconnectivity, impairment in locomotion, and anxiety-related hypervelocity in tsc2 mutants. (A) Quantification of activation of TrkB receptor judged by levels of P-TrkB and ratio of P-TrkB to TrkB by immunochemistry (ELISA) revealed higher activation levels in tsc2 fish compared with control siblings and a decrease after ANA-12 treatment [P-TrkB: H = 4.355, P = 0.049; P = 0.05, tsc2 vs. tsc2 (Dunn’s test)]; P = 0.015, tsc2 untreated vs. treated with ANA-12 (Dunn’s test); P-TrkB/TrkB: H = 5.689, P = 0.05; P = 0.05, tsc2 vs. tsc2 (Dunn’s test); P = 0.049, tsc2 untreated vs. treated with ANA-12 (Dunn’s test)]. (B) Quantification of levels of Creb phosphorylation by immunochemistry (ELISA) revealed higher levels in tsc2 compared with controls and a decrease after ANA-12 treatment [genotype: F = 3.513, P = 4.66 × 10−4; treatment: F = 14.759, P = 8.33 × 10−4; genotype × treatment: P > 0.05; P = 0.012, tsc2 after ANA-12 vs. DMSO treatment (Tukey HSD test); P = 0.033, untreated tsc2 vs. tsc2 (Tukey HSD test)]. (C) Survival probability of tsc2 after various treatments. (D) Confocal images of tsc2 brains that were immunostained with anti–P-Rps6 antibody after ANA-12 treatment. (Scale bar, 30 µm.) (E) AC width in tsc2 after various treatments, including representative confocal images and quantification [F = 5.83, P = 0.00142; P = 0.002 for DMSO vs. ANA-12, P = 0.049 for DMSO vs. Rapa pretreatment (Dunnett’s test)]. (Scale bar, 30 µm.) (F) Cumulative activity of tsc2 after treatment with ANA-12 compared with tsc2 and tsc2 fish over 1 h of tracking, showing an increase in activity of mutant fish after treatment [H = 16.652, P = 2.42 × 10−4; P = 0.0172, tsc2 untreated vs. treated with ANA-12 for 24 h (Dunn’s test)]. (G) Cumulative activity of the tsc2 after the prevention of disease development by Rapa pretreatment compared with tsc2 and tsc2 fish over 1 h of tracking, showing an increase in activity of mutant fish after treatment [H = 32.18, P = 3.9 × 10−8; P = 2.0 × 10−8 for tsc2 untreated vs. rapamycin pretreatment (Dunn’s test)]. (H) Cumulative activity of tsc2 after the treatment with VGN or VGN-P to prevent disease development, respectively, compared with tsc2 and tsc2 fish over 1 h of tracking, showing improvements in activity after short VGN treatment but toxicity after longer treatment with VGN [H = 19.262, P = 6.566 × 10−5; P = 3.4 × 10−5 for tsc2 untreated vs. treated with VGN, P > 0.05 for tsc2 untreated vs. VGN-P (Dunn’s test)]. (I) Average velocity of high-velocity movements of tsc2 compared with tsc2 and tsc2 fish after treatment with ANA-12 [H = 14.686, P = 6.47 × 10−4; P = 0.015 for tsc2 untreated vs. treated with ANA-12 for 3 h, P = 0.003 for tsc2 untreated vs. treated with ANA-12 for 24 h (Dunn’s test)]. (J) Average velocity of high-velocity movements of tsc2 fish after the prevention of disease development with Rapa pretreatment compared with tsc2 and tsc2 fish [H = 29.68, P = 4.52 × 10−5; P > 0.05 for tsc2 untreated vs. tsc2 with Rapa pretreatment (Dunn’s test)]. (K) Average velocity of high-velocity movements of tsc2 after the treatment with VGN or VGN-P to prevent disease development, respectively, compared with tsc2 and tsc2 fish (H = 3.286, P = 0.19). *P < 0.05, **P < 0.01, ***P < 0.005, ns: not significant. Treatment with ANA-12 increased survival of tsc2 mutants more than treatment with vigabatrin (VGN), which is the first-line drug for the treatment of TSC-associated epilepsy. However, ANA-12 was not as effective in restoring survival of tsc2 as pretreatment with the direct mTorC1 inhibitor rapamycin (RapaP) or pretreatment with VGN (VGN-P; Fig. 5 and ). ANA-12 did not alter activation of the mTorC1 pathway in the brain of tsc2 (Fig. 5) but restored the proper width of the AC when administered at 48 hpf, similar to the effect of RapaP (Fig. 5 and ). Moreover, the seizure-associated decreased activity of tsc2 was rescued by ANA-12 as potently as by VGN or Rapa-P (Fig. 5 ). ANA-12 also decreased the number of PTZ-induced bursts and increased time without bursting (). The increased high-range velocity in tsc2, reflecting anxiety-like behavior, was fully rescued only by ANA-12 treatment as well (Fig. 5 ). Moreover, VGN did not alter the increase in high-range velocity in mutant fish (Fig. 5), further suggesting that the increase in velocity was not caused by partial seizures but indeed reflected anxiety-like behavior. Therefore, reducing TrkB signaling effectively treated both epilepsy- and anxiety-associated behavioral changes and brain dysconnectivity. The above-described droplet digital PCR (ddPCR) results () pointed to Dock-Elmo-Rac1 pathway up-regulation. TrkB activates the Rac1 pathway in neurons (30); thus we hypothesized that up-regulation of Rac1 activity contributes to the tsc2 phenotype. Treatment with the Rac1 inhibitor W56 (200 nM) did not affect total activity but resulted in lower high-range velocity of tsc2 compared to tsc2 (), thereby rescuing an anxiety-like parameter. Collectively, our data implicate TrkB hyperactivity in many aspects of TSC pathology, suggesting also a role for Rac1 in TSC-related anxiety.

Discussion

TSC symptoms arise during brain development through mechanisms that are not fully understood. In the present study, tsc2 exhibited pallium malformations and thinner commissures, which were rescued by TrkB inhibition, together with behavioral abnormalities, suggesting that the observed neurological phenotypes were related to neuroanatomical changes. The thinner AC width in tsc2 mutants may reflect the WM thinning seen in TSC patients, which is associated with seizures (12, 20–22). In TSC patients, decreased density of the corpus callosum is correlated with epilepsy and such TANDs as autism and ID (22). Moreover, patients with TSC-associated refractory epilepsy have thinner and disorganized axon tracts (12). Similar fasciculation disturbances were seen in tsc2 ptf1a:GFP-positive axons in the present study. These disturbances may result from impairments in axonal pathfinding and elongation. Consistently, previous studies found that lack of Tsc1 induces ectopic axons in vitro and WM defects in mice (31). The axon guidance pathways are regulated by external cues and their receptors that in turn activate a Dock–Elmo protein complex that subsequently activates Rac1, resulting in actin dynamics. Dock-3 and Dock-4 play pivotal roles in axon development. Dock-3 promotes axonal growth, forming the conventional Dock–Elmo complex, which is important for Rac1 activation in response to BDNFTrkB signaling. Dock-4 promotes neurite differentiation to establish axon-dendrite polarity (32). Interestingly, in the present study, dock3, dock4, elmo2, and rac1 mRNA levels were higher in tsc2 than in tsc2+/+. We further confirmed increased Dock4- and Elmo2-protein levels in tsc2 fish brains. Moreover, inhibition of Rac1 rescued anxiety-related tsc2 velocity, but did not affect decreased locomotion, suggesting that Rac1 involvement in anxiety-related behavior is separate from epilepsy. Recently, zebrafish has become an accepted model for neuropsychiatric studies having applications in translational research. Zebrafish as highly complex vertebrates present a repertoire of complicated behaviors that can be used to study neurological and neuropsychiatric human disorders (33, 34). In the present study, tsc2 mutants exhibited lower activity but higher high-range velocity, suggesting that they swam in a burst-like manner. These high-amplitude movements can be caused by such TAND-related phenotypes as overactivity, impaired impulse control, or anxiety. Increased high-range velocity cannot represent hyperactivity because tsc2 total locomotion decreased. We hypothesized that the increased velocity of tsc2 resulted from anxiety-like behavior and the open field, sudden-light changes test and elevated cortisol levels confirmed this. However, the increased velocity could be potentially caused by impaired impulse control, which could explain the results of the light-preference test (higher risk taking and boldness) and would contradict the results of the open field. Impaired impulsivity would possibly result in elevated cortisol and hyperactive bursts, similar to the effects produced by anxiety. Therefore, we performed a startle analysis to repeated dark flashes which is relevant to anxiety, impulsivity, and ID reflected by escape responses to startling stimuli and habituation after repetition. tsc2 exhibited lower or delayed response to the first startle stimulus compared with tsc2 that exhibited no difference in habituation. This did not confirm higher impulsivity in tsc2 and further suggested anxiety as a cause for the observed phenotypes. Because tsc2 fish remained at the edges of the well in the light–dark test, we propose that tsc2 suffer brain impairments and cannot react to dark conditions similarly to tsc2. Startle response results do not necessarily contradict this hypothesis. Although we did not see differences in habituation of the tsc2 response compared with controls, the response to the startling stimulus was already impaired. Supporting the possibility of ID, we found perturbances in the fasciculation of ptf1a:GFP-positive tracts from the posterior tuberculum in tsc2, which may impair anxiety regulation. Another brain part, the habenula, is critical for processing emotions, social behavior, anxiety responses, and locomotion, and it is thought to act as a link between the forebrain and midbrain to produce emotional responses (35–37). The left habenula has been shown to regulate light preference behavior in zebrafish larvae (38). Other left–right asymmetries in brain morphology have also been linked to regulation of boldness and exploratory behavior (39). Therefore, it is likely that aberrant development of the brain hemisphere connections is responsible for the observed TAND-related phenotypes. Both the increased anxiety-like behavior in the open field and when subjected to sudden changes in light and the lack of light preference in tsc2 may thus result from disturbances in overall connectivity to the habenula. Anxiety-like behavior can be induced by seizures (40), providing a link between epileptogenesis, seizures, and anxiety. Reductions of BDNF signaling in the hippocampus were shown to prevent spontaneous seizures and rescue anxiety-like behavior in rodent epilepsy models (26). Consistently, sustained Creb activity was shown to produce seizures in mice (41). In the present study, ANA-12 treatment rescued the activity impairment and reversed increased high-range velocity in tsc2. At the same time, ANA-12 also reduced TrkB and Creb activation and lowered the seizure threshold in tsc2, implicating TrkB signaling in epileptogenesis. Reversal of AC thinning and anxiety-related hypervelocity by ANA-12 but not by VGN suggests that commissural connections substantially contribute to regulating anxiety and links brain anatomy with behavior. These results also implicate TrkB hyperactivity in both commissure development and anxiety. We also showed that Rac1 inhibition, similar to inhibition of TrkB, rescued anxiety-related velocity of tsc2. In line with our results, Rac1 overactivation was previously shown to inhibit the formation of long-term fear conditioning memory (42). Rac1 is required for commissural axon development specifically in the cortex and controls axon crossing through the AC and corpus callosum in mice (43, 44). tsc2 exhibited thinner AC and presented problems with axons crossing the brain midline. Therefore, it is probable that the disruption of commissural axons results in anxiety through Rac1. Moreover, Rac1 may act downstream of TrkB in axon development and synaptic crosstalk (30, 45, 46), raising an intriguing possibility that, also in TSC, TrkB hyperactivity results in anxiety, causing Rac1 pathway dysregulation. Nevertheless, hyperactive Rac1/3 also caused excitatory–inhibitory imbalance and increased brain activity with impaired synchronization (47). This is coherent with our results as tsc2 exhibited higher brain activity and seizures. However, it is also possible that Rac1 affects anxiety by impairing synaptic crosstalk in other brain regions, independently from commissures. Finally, although we do see similar effects of ANA-12 and Rac1 inhibitors on anxiety-like behavior in zebrafish and it is plausible that their targets act in one pathway, we only hypothesize a direct link. In conclusion, the presented results implicate TrkB and Rac1 signaling in the pathology of TSC, expanding our understanding of the complex mechanisms that underlie this disease and revealing a potential therapeutic target.

Methods

Drug Treatments.

PTZ, RA, VGN, ethosuximide, and ANA-12 were purchased from Sigma-Aldrich. Rapamycin, diazepam, and W56 were obtained from MBL International, Cefarm S.A, and Tocris, respectively. Drugs were dissolved in E3, dimethylsulfoxide (DMSO), or glycerol for stock solutions, and were further diluted in E3. Drugs were administered directly into E3 with the same number of dechorionated fish. More information can be found in .

Image Acquisition and Analyses.

Fluorescence images of cryosections and whole mounts were acquired with a Zeiss LSM800 confocal microscope. For STFBC, living embryos in the chorions were recorded using a Leica M60 microscope with a DMC2900 camera every 10 ms for 3 min. Other in vivo imaging was performed with a Lighsheet Z.1 microscope (Zeiss). Image analyses were performed using Fiji (fiji.sc) (48) with a measurement tool, Skeletonize (2D/3D) (49), or 3D-Sholl analysis (50). Further details can be found in .

Behavioral Analyses.

The behavioral measurements were performed using the ViewPoint Zebrabox high-throughput monitoring system. Activity was recorded in separate velocity categories: inactivity (<0.5 cm/s), free-swimming (0.5–2 cm/s), and high-speed movements (>2 cm/s) (23). Data were gathered by Zebralab (ViewPoint) and analyzed with RStudio (rstudio.com). Further details can be found in .

Additional Materials and Methods.

Additional information about the materials and methods, including zebrafish breeding and genotyping, immunofluorescence, ELISA, RNA extraction, cDNA synthesis, ddPCR, Western blot, statistical analyses, and experimental design can be found in .

Material and Data Availability.

Manuscript and contain all data with the representative images only. The fish lines, materials, protocols, or imaging data are available upon reasonable request of the corresponding authors.
  47 in total

Review 1.  Fear, anxiety, and control in the zebrafish.

Authors:  Suresh Jesuthasan
Journal:  Dev Neurobiol       Date:  2012-03       Impact factor: 3.964

Review 2.  Brain-derived neurotrophic factor and the development of structural neuronal connectivity.

Authors:  Susana Cohen-Cory; Adhanet H Kidane; Nicole J Shirkey; Sonya Marshak
Journal:  Dev Neurobiol       Date:  2010-04       Impact factor: 3.964

3.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

4.  Rac1 controls the formation of midline commissures and the competency of tangential migration in ventral telencephalic neurons.

Authors:  Lei Chen; Guanghong Liao; Ronald R Waclaw; Kevin A Burns; Diana Linquist; Kenneth Campbell; Yi Zheng; Chia-Yi Kuan
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

5.  Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice.

Authors:  David M Feliciano; Tiffany Su; Jean Lopez; Jean-Claude Platel; Angélique Bordey
Journal:  J Clin Invest       Date:  2011-03-14       Impact factor: 14.808

6.  Tuberous sclerosis complex proteins control axon formation.

Authors:  Yong-Jin Choi; Alessia Di Nardo; Ioannis Kramvis; Lynsey Meikle; David J Kwiatkowski; Mustafa Sahin; Xi He
Journal:  Genes Dev       Date:  2008-09-15       Impact factor: 11.361

7.  Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs.

Authors:  Matthew J Winter; William S Redfern; Amanda J Hayfield; Stewart F Owen; Jean-Pierre Valentin; Thomas H Hutchinson
Journal:  J Pharmacol Toxicol Methods       Date:  2008-02-09       Impact factor: 1.950

8.  Prenatal diagnosis of cerebral lesions in Tuberous sclerosis complex (TSC). Case report and review of the literature.

Authors:  S B Wortmann; A Reimer; J W T Creemers; R A Mullaart
Journal:  Eur J Paediatr Neurol       Date:  2007-08-02       Impact factor: 3.140

Review 9.  The developing utility of zebrafish models of neurological and neuropsychiatric disorders: A critical review.

Authors:  Barbara D Fontana; Nathana J Mezzomo; Allan V Kalueff; Denis B Rosemberg
Journal:  Exp Neurol       Date:  2017-10-05       Impact factor: 5.330

10.  Phylogeny and ontogeny of the habenular structure.

Authors:  Hidenori Aizawa; Ryunosuke Amo; Hitoshi Okamoto
Journal:  Front Neurosci       Date:  2011-12-21       Impact factor: 4.677

View more
  9 in total

1.  G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling.

Authors:  Mirja Tamara Prentzell; Ulrike Rehbein; Marti Cadena Sandoval; Ann-Sofie De Meulemeester; Ralf Baumeister; Laura Brohée; Bianca Berdel; Mathias Bockwoldt; Bernadette Carroll; Suvagata Roy Chowdhury; Andreas von Deimling; Constantinos Demetriades; Gianluca Figlia; Mariana Eca Guimaraes de Araujo; Alexander M Heberle; Ines Heiland; Birgit Holzwarth; Lukas A Huber; Jacek Jaworski; Magdalena Kedra; Katharina Kern; Andrii Kopach; Viktor I Korolchuk; Ineke van 't Land-Kuper; Matylda Macias; Mark Nellist; Wilhelm Palm; Stefan Pusch; Jose Miguel Ramos Pittol; Michèle Reil; Anja Reintjes; Friederike Reuter; Julian R Sampson; Chloë Scheldeman; Aleksandra Siekierska; Eduard Stefan; Aurelio A Teleman; Laura E Thomas; Omar Torres-Quesada; Saskia Trump; Hannah D West; Peter de Witte; Sandra Woltering; Teodor E Yordanov; Justyna Zmorzynska; Christiane A Opitz; Kathrin Thedieck
Journal:  Cell       Date:  2021-01-25       Impact factor: 41.582

2.  stim2b Knockout Induces Hyperactivity and Susceptibility to Seizures in Zebrafish Larvae.

Authors:  Iga Wasilewska; Rishikesh Kumar Gupta; Bartosz Wojtaś; Oksana Palchevska; Jacek Kuźnicki
Journal:  Cells       Date:  2020-05-21       Impact factor: 6.600

3.  Antidepressant Screening Demonstrated Non-Monotonic Responses to Amitriptyline, Amoxapine and Sertraline in Locomotor Activity Assay in Larval Zebrafish.

Authors:  Michael Edbert Suryanto; Gilbert Audira; Boontida Uapipatanakul; Akhlaq Hussain; Ferry Saputra; Petrus Siregar; Kelvin H-C Chen; Chung-Der Hsiao
Journal:  Cells       Date:  2021-03-26       Impact factor: 6.600

4.  Phenotypic analysis of catastrophic childhood epilepsy genes.

Authors:  Aliesha Griffin; Colleen Carpenter; Jing Liu; Rosalia Paterno; Brian Grone; Kyla Hamling; Maia Moog; Matthew T Dinday; Francisco Figueroa; Mana Anvar; Chinwendu Ononuju; Tony Qu; Scott C Baraban
Journal:  Commun Biol       Date:  2021-06-03

5.  Leukocyte invasion of the brain after peripheral trauma in zebrafish (Danio rerio).

Authors:  Xiang-Ke Chen; Joseph Shiu-Kwong Kwan; Gordon Tin-Chun Wong; Zhen-Ni Yi; Alvin Chun-Hang Ma; Raymond Chuen-Chung Chang
Journal:  Exp Mol Med       Date:  2022-07-13       Impact factor: 12.153

Review 6.  Teleost Fish and Organoids: Alternative Windows Into the Development of Healthy and Diseased Brains.

Authors:  Giulia Fasano; Claudia Compagnucci; Bruno Dallapiccola; Marco Tartaglia; Antonella Lauri
Journal:  Front Mol Neurosci       Date:  2022-08-11       Impact factor: 6.261

7.  Hyperactivation of mTORC1 in a double hit mutant zebrafish model of tuberous sclerosis complex causes increased seizure susceptibility and neurodevelopmental abnormalities.

Authors:  Ann-Sofie De Meulemeester; Lise Heylen; Aleksandra Siekierska; James D Mills; Alessia Romagnolo; Nicole N Van Der Wel; Eleonora Aronica; Peter A M de Witte
Journal:  Front Cell Dev Biol       Date:  2022-09-27

8.  Knockout of stim2a Increases Calcium Oscillations in Neurons and Induces Hyperactive-Like Phenotype in Zebrafish Larvae.

Authors:  Rishikesh Kumar Gupta; Iga Wasilewska; Oksana Palchevska; Jacek Kuźnicki
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

9.  Zebrafish Larvae Carrying a Splice Variant Mutation in cacna1d: A New Model for Schizophrenia-Like Behaviours?

Authors:  Nancy Saana Banono; Kinga Gawel; Linus De Witte; Camila V Esguerra
Journal:  Mol Neurobiol       Date:  2020-10-14       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.